Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer |
| Type de publication | Journal Article |
| Year of Publication | 2020 |
| Auteurs | Neuzillet C, Casadei-Gardini A, Brieau B, Vivaldi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet A-L, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Le Sourd S, Evesque L, Meurisse A, Lievre A, Vernerey D, Boussaha T, Heurgue A, Desrame J, Lecomte T, Cacheux W, Bachet J-B, Phelip J-M, Hautefeuille V, Mary F, Locher C, Bidault-Thirot A, Marthey L, Touchefeu Y, Moulin V, Zaanan A, Taieb J, Casagrande M, Murgioni S, Santini D, Fornaro L, Montagnani F, Leone F, Faloppi L, Giommoni E, Lutrino SEufemia, Palloni A, Brunetti O, Argentiero A, Bergamo F, Vasile E, Lai E, Ziranu P, Dadduzio V, Rizzato M, Pellino A, Aglietta M, Cappetta A, Garattini SKen, Basile D, Hammoudi N, Puzzoni M, Onc AGEOAssoc Gast, Cholangiocarcinom GICOItalian Gr |
| Journal | INTERNATIONAL JOURNAL OF CANCER |
| Volume | 147 |
| Pagination | 3177-3188 |
| Date Published | DEC 1 |
| Type of Article | Article |
| ISSN | 0020-7136 |
| Mots-clés | cholangiocarcinoma, combination chemotherapy, monotherapy, Overall survival, palliative chemotherapy |
| Résumé | {Fluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred option in advanced biliary tract cancer (aBTC) (ABC-06 phase III trial). However, the overall survival (OS) benefit was limited and comparison with FP monotherapy was not available. Our aim was to assess the OS of patients treated with a FP monotherapy compared to a doublet with irinotecan or platinum in L2. We performed a retrospective analysis of two large multicenter prospective cohorts: a French cohort (28 centers) and an Italian cohort (9 centers). All consecutive patients with aBTC receiving FP-based L2 after gemcitabine plus cisplatin/gemcitabine plus oxaliplatin L1 between 2003 and 2016 were included. A subgroup analysis according to performance status (PS) and an exploratory analysis according to platinum sensitivity in L1 were planned. In the French cohort (n = 351), no significant OS difference was observed between the FP monotherapy and doublet groups (median OS: 5.6 vs 6.8 months |
| DOI | 10.1002/ijc.33146, Early Access Date = {JUL 2020 |